Creo Medical Group’s (CREO) “House Stock” Rating Reaffirmed at Shore Capital Group

Shore Capital Group reaffirmed their house stock rating on shares of Creo Medical Group (LON:CREO) in a research note released on Thursday morning, MarketBeat Ratings reports. The firm currently has a GBX 40 price target on the stock.

Creo Medical Group Stock Down 1.4%

Shares of CREO opened at GBX 13.67 on Thursday. The company’s 50-day simple moving average is GBX 13.70 and its 200-day simple moving average is GBX 13.30. The company has a debt-to-equity ratio of 8.20, a quick ratio of 2.19 and a current ratio of 3.22. Creo Medical Group has a 1 year low of GBX 9.52 and a 1 year high of GBX 18.50. The stock has a market capitalization of £66.43 million, a PE ratio of 13.67 and a beta of 1.62.

Creo Medical Group (LON:CREO) last announced its quarterly earnings data on Friday, May 22nd. The company reported GBX (0.04) earnings per share for the quarter. Creo Medical Group had a net margin of 88.33% and a return on equity of 9.56%. The business had revenue of GBX 600 million during the quarter. Analysts forecast that Creo Medical Group will post -10.0800005 earnings per share for the current fiscal year.

Insider Buying and Selling at Creo Medical Group

In related news, insider Richard John Rees acquired 6,250 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were acquired at an average price of GBX 14 per share, with a total value of £875. Also, insider Craig Jonathan Gulliford acquired 6,250 shares of Creo Medical Group stock in a transaction dated Wednesday, July 1st. The stock was bought at an average price of GBX 14 per share, for a total transaction of £875. Insiders own 6.92% of the company’s stock.

Creo Medical Group Company Profile

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.